First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

被引：2
|
作者：
Soria, J.
De Braud, F. G.
Cereda, R.
Bahleda, R.
Delmonte, A.
Angevin, E.
Varga, A.
Noberasco, C.
Dall'O, E.
Lassau, N.
Dromain, C.
Bellomi, M.
Farace, F.
Bertolini, F.
Zucchetti, M.
Marsoni, S.
Camboni, M. G.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] European Inst Oncol, Milan, Italy
[3] EOS SpA, Milan, Italy
[4] SENDO, Milan, Italy
[5] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS149
引用
收藏
页数：1
相关论文
共 50 条
  • [11] First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.
    Doi, Toshihiko
    Yoh, Kiyotaka
    Shitara, Kohei
    Takahashi, Hideaki
    Ueno, Makoto
    Kobayashi, Satoshi
    Morimoto, Manabu
    Ohkawa, Shinichi
    Okusaka, Takuji
    Ueno, Hideki
    Morizane, Chigusa
    Shiba, Satoshi
    Okano, Naohiro
    Naruge, Daisuke
    Nagashima, Fumio
    Furuse, Junji
    Koba, Kazuo
    Noguchi, Kazuharu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [12] Update on first-in-man trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors
    Wainberg, Zev A.
    de Bono, Johann S.
    Mina, Lida
    Sachdev, Jasgit
    Byers, Lauren Averett
    Chugh, Rashmi
    Zhang, Charlie
    Henshaw, Joshua W.
    Dorr, Andrew
    Glaspy, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [13] Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.
    Rosen, L. S.
    Wilding, G.
    Sweeney, C.
    Casale, D.
    Kollia, G.
    Wu, C.
    Ayers, M.
    Hill, C.
    Galbraith, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 133S - 133S
  • [14] A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.
    Delord, Jean-Pierre
    Awada, Ahmad
    Raymond, Eric
    Lokiec, Francois
    Herait, Patrice
    Rezai, Keyvan
    Lachaux, Nicolas
    Rabinovich, Gabriel A.
    Gomez-Roca, Carlos
    Aftimos, Philippe
    Faivre, Sandrine
    Carlos Stupirski, Juan
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [15] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] A phase I open-label study of FGFR/VEGFR inhibitor FH-2001 in patients with advanced solid tumors
    Song, Zhengbo
    Hui, Ai-min
    Wu, Zhuli
    Liu, Huilong
    Cheng, Xiangdong
    CANCER RESEARCH, 2022, 82 (12)
  • [17] First-in-human Phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors.
    Hollebecque, Antoine
    Soria, Jean-Charles
    Bahleda, Ratislav
    Lopez-Busto, Natividad
    Jacquet-Bescond, Anne
    Burbridge, Mike F.
    Valerie, Cattan
    Pauly, Jeanne
    Herranz, Maria
    Azaro, Analia
    Depil, Stephane
    Rodon, Jordi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [18] First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Yan, Li
    Patnaik, Amita
    Fearen, Ivy
    Olmos, David
    Papadopoulos, Kyriakos
    Baird, Richard D.
    Delgado, Liliana
    Taylor, Adekemi
    Lupinacci, Lisa
    Riisnaes, Ruth
    Pope, Lorna L.
    Heaton, Simon P.
    Thomas, George
    Garrett, Michelle D.
    Sullivan, Daniel M.
    de Bono, Johann S.
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4688 - 4695
  • [19] A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
    Xu, Ruihua
    Li, Yuhong
    Ji, Jiao
    Qiu, Miaozhen
    Zhang, Yang
    Liu, Wenqin
    Tian, Xiaohong
    Li, Su
    Wang, Hengbang
    Wang, Fenghua
    Zhang, Dongsheng
    Wang, Feng
    Wang, Zhiqiang
    Luo, Huiyan
    Zou, Benyan
    Wang, De shen
    Ren, Chao
    Jin, Ying
    Zhai, Yifan
    Yang, Dajun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [20] First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
    Tsimberidou, Apostolia Maria
    de Achaval, Sofia
    Alibhai, Imran
    Kaseb, Ahmed Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345